drugset / Trial / NCT01196455

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

NCT01196455

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.

Timeline

Start
2006-03
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Mitomycin C Other / unclassified 8 mg/m2 Intravenous